Get the Stockscreener App
67.57
0.40%
0.27
After Hours:
67.75
0.18
+0.27%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $67.57, with a volume of 6.21M.
It is up +0.40% in the last 24 hours and up +1.21% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$67.30
Open:
$68.04
24h Volume:
6.21M
Relative Volume:
1.09
Market Cap:
$224.59B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
27.14
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
-6.72%
1M Performance:
+1.21%
6M Performance:
+4.78%
1Y Performance:
-12.94%
1-Day Range:
$67.52
$68.63
1-Week Range:
$67.26
$72.69
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.57 | 224.59B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca’s Imfinzi shows promise in bladder cancer trial By Investing.com - Investing.com UK
AstraZeneca posts positive data for Imfinzi in bladder cancer (AZN:NASDAQ) - Seeking Alpha
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens By Stocktwits - Investing.com India
AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication - Medical Dialogues
AstraZeneca’s Imfinzi delays bladder cancer return in high-risk patients - Proactive Investors
AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC - DirectorsTalk Interviews
Astrazeneca Says Imfinzi Improved DFS In Early Bladder Cancer - marketscreener.com
AstraZeneca (AZN) Sees Increased Bullish Option Activity | AZN Stock News - GuruFocus
US court shuts down AstraZeneca's challenge to Medicare drug price plan - Reuters
Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class ActionAZN - ACCESS Newswire
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
June 27th Options Now Available For AstraZeneca - Nasdaq
AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1) - Bloomberg Law News
Britain set to strike first deal to cut Trump tariffs - marketscreener.com
Does the GSK or AstraZeneca share price currently offer the best value? - MSN
AstraZeneca (AZN) Achieves Key Milestone with Enhertu in Breast Cancer Trial - GuruFocus
AstraZeneca marks Enhertu trial win in breast cancer (AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - Yahoo Finance
AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study - marketscreener.com
First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment - insights.citeline.com
ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY- - marketscreener.com
AstraZeneca (AZN) Sees Positive Results in DESTINY-Breast11 Trial | AZN Stock News - GuruFocus
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief - Proactive Investors
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.
AstraZeneca and GSK Share Price Slide as Markets React to Vinay Prasad’s FDA Appointment - paginasiete.bo
AstraZeneca plc (LON: AZN) Shares Fall 2.2% in Early Morning Trading - paginasiete.bo
REGAstraZeneca PLCEnhertu improved pCR in early-stage breast cancer - TradingView
AstraZeneca (AZN): Impact of FDA's New Inspection Strategy on Fo - GuruFocus
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing - Yahoo Finance
AstraZeneca unveils $300M Rockville investment, a boost for MoCo amid federal cuts - The Business Journals
Berenberg: AstraZeneca, Eli Lilly Among Pharmaceutical Companies Set to Gain from US 'Pill Penalty' Update - marketscreener.com
AstraZeneca's (AZN) Calquence Gains EU Approval for Mantle Cell Lymphoma Treatment | AZN Stock News - GuruFocus
AstraZeneca's Calquence gets Europe approval for MCL - Sharecast.com
AstraZeneca Plc Calquence combo approved in EU for first-line MCL - DirectorsTalk Interviews
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma - marketscreener.com
AstraZeneca: EU Approves Calquence Combination For 1st-line Mantle Cell Lymphoma - Nasdaq
AstraZeneca Says Calquence Combination Approved In EU For 1L MCL - marketscreener.com
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye - Yahoo Finance
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN - GuruFocus
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN) | AZN Stock News - GuruFocus
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Yahoo Finance
AstraZeneca reports success in phase III asthma trials By Investing.com - Investing.com India
AstraZeneca reports success in phase III asthma trials - Investing.com
AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials - Reuters
AstraZeneca (AZN) Achieves Major Milestones in Asthma Treatment Trials - GuruFocus
AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials - insights.citeline.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):